Amarantus Bioscience Holdings Inc (AMBS)

[zoomboom]

Orphan drug development has several advantages:

It takes just under 5 years from Phase 2 clinical trial to market, as opposed to 6 to 8 years for traditional drug approval
Orphan designations have better odds for approval with an 82% success rate (Phase 2 forward) as opposed to 35% for traditional drugs
Orphan products have attractive profitability given the smaller patient populations, which drive premium pricing and lower cost of sales
Orphan products experience ongoing revenue growth due to steady uptake after launch with chronic, lifetime customers
Orphan products experience significant competitive advantage to being first to market